TP53 and myelodysplastic syndrome: Herein, we discuss the features of TP53 mutations within MDS, their corresponding carcinogenic mechanisms, their predictive value in current standard treatments including hypomethylating agents (HMAs), allogeneic hematopoietic stem cell transplantation (HSCT), and lenalidomide, together with the latest progress in TP53-targeted therapy strategies, especially MDS clinical trial data.